

CORRIGENDUM

DOI: 10.3892/ijo.2023.5583

Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth

ZI-XUE XUAN, LIN-NA LI, QI ZHANG, CHENG-WANG XU, DE-XUAN YANG, YE YUAN, YING-HONG AN, SHAN-SHAN WANG, XIAO-WEN LI and SHOU-JUN YUAN

Int J Oncol 45: 2411-2420, 2014; DOI: 10.3892/ijo.2014.2690

Subsequently to the publication of the above paper, an interested reader drew to the authors' attention that, for the scratch wound assay experiments shown in Fig. 1 on p. 2413, the panels showing the '0 h' experiments for the respective incubations with VEGF or BC001 were apparently identical.

The authors were able to re-examine their original data files, and realized that this figure had been inadvertently assembled incorrectly. The revised version of Fig. 1, containing the correct data for the '0 h / BC001' panel, is shown below. Note that the revisions made to this figure do not affect the overall conclusions reported in the paper. The authors are grateful to the Editor of *International Journal of Oncology* for allowing them the opportunity to publish this Corrigendum, and apologize to the readership for any inconvenience caused.



Copyright © 2023 Xuan et al. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.




Figure 1. BC001 inhibits endothelial cells migration. After incubation with BC001, the migrated cells were decreased, compared to that of VEGF(+) group, this result showed BC001 inhibited HUVEC migration. Scale bar, 400 µm.